#phase2trial — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #phase2trial, aggregated by home.social.
-
DATE: May 20, 2026 at 09:49AM
SOURCE: PSYCHIATRIC TIMESDirect article link at end of text block below.
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
https://t.co/J7IuDAs5XiHere are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SynendosTherapeutics #SYT510 #EndocannabinoidModulator #GeneralizedAnxiety #Phase2Trial
-
DATE: May 20, 2026 at 09:49AM
SOURCE: PSYCHIATRIC TIMESDirect article link at end of text block below.
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
https://t.co/J7IuDAs5XiHere are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SynendosTherapeutics #SYT510 #EndocannabinoidModulator #GeneralizedAnxiety #Phase2Trial
-
DATE: May 20, 2026 at 09:49AM
SOURCE: PSYCHIATRIC TIMESDirect article link at end of text block below.
Synendos Therapeutics has initiated dosing in a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety disorder symptoms with improved safety and adherence. @synendos
https://t.co/J7IuDAs5XiHere are any URLs found in the article text:
Articles can be found by scrolling down the page at Articles can be found at https://www.psychiatrictimes.com/news".
-------------------------------------------------
DAILY EMAIL DIGEST: Email [email protected] -- no subject or message needed.
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
NYU Information for Practice puts out 400-500 good quality health-related research posts per week but its too much for many people, so that bot is limited to just subscribers. You can read it or subscribe at @PsychResearchBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #psychotherapist #SynendosTherapeutics #SYT510 #EndocannabinoidModulator #GeneralizedAnxiety #Phase2Trial
-
https://www.europesays.com/dk/47939/ Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes #Biotechnology #ChinesePatients #GlobalPhase #JacobMartin #NovoNordisk #Phase2Trial #TUL #Type2Diabetes
-
https://www.europesays.com/dk/47899/ Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes #Biotechnology #ChinesePatients #GlobalPhase #JacobMartin #NovoNordisk #Phase2Trial #TUL #Type2Diabetes
-
Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
#YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67438 -
Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
#YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67438 -
Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
#YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67438 -
Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
#YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67438 -
Jefferies maintains its 'Buy' rating on Insmed, citing strong expectations for Phase 2 trial results of its PAH treatment TPIP, which could challenge current standard therapies.
#YonhapInfomax #Insmed #Jefferies #TPIP #Phase2Trial #PulmonaryVascularResistance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67438